In The News
Judge approves $57.5M ANZ class action settlement, funder’s ATE costs
IC Markets CEO hit with guillotine orders for filing defence
Lawyers for Banksia class action funder face possible court action
CIMIC settles shareholder class action for $45.25M
Boral wins challenge to CEO cross-examination in class actions
Hytera can’t dodge ‘substantial industrial theft’ finding in Motorola case
Barrister who accepted briefs for appearances on same day referred to watchdog
Judge approves $31.5M settlement in junior doctors class action
ASIC claims crypto firm Binance denied protections to derivatives investors
Melbourne law firm argues 700 clients can’t sue for negligence in class action
Please login to bookmarkClose

Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent. 

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au